|
|
|
| Clinical Efficacy and Safety of Radiofrequency Ablation Combined with DC-CIK Immunotherapy for Advanced Primary Liver Cancer |
| WU Wei |
| Yangpu hospital,Tongji University, Shanghai 200092 |
|
|
|
|
Abstract 【Objective】 To study the efficacy and safety of radiofrequency ablation of (RFA) combined with dendritic cells-cytokines-induced killer cells (DC-CIK) in the treatment of advanced primary liver cancer. 【Methods】 A total of 86 patients with advanced primary liver cancer in our hospital from January 2018 to June 2019 were selected and randomly divided into control group (treated with RFA) and observation group (treated with RFA combined with DC-CIK immunotherapy), 43 cases in each group. The serum indexes, immune function, liver function and survival of patients were observed before and after treatment, and the short-term efficacy and incidence of adverse reactions were compared between the two groups.【Results】 The disease control rate of the observation group was 79.07% (34/43), which was significantly higher than 41.86% (18/43) of the control group (P<0.05). After treatment, the levels of serum alpha fetoprotein (AFP), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF) in the observation group were significantly decreased (P<0.05), and were lower than those in the control group (P<0.05); while the levels of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin (TBIL) in the observation group were higher than those before treatment, and were lower than those in the control group, the difference was statistically significant (P<0.05).The CD3+、CD4+、CD4+/CD8+ of peripheral blood T cell subsets in the observation group were significantly higher than those before treatment, and were significantly higher than those in the control group, the difference was statistically significant (P<0.05). The incidence of adverse reactions in the observation group was 27.91% (12/43), which was higher than 23.26% (10/43) in the control group, and the difference was not statistically significant (P>0.05). The 1-year and 3-year survival rates of the observation group were significantly higher than those of the control group (all P<0.05).【Conclusion】 RFA combined with DC-CIK immunotherapy is effective in the treatment of patients with advanced primary liver cancer. It can reduce the level of serum tumor markers, improve the immune function, reduce the degree of liver function damage, prolong the survival rate, and has good safety, which is worthy of clinical application.
|
|
Received: 18 July 2019
|
|
|
|
|
|
[1] Stintzing S,Grothe A, Hendrich S, et al. Percutaneous radiofrequency ablation (RFA) or robotic radiosurgery (RRS) for salvage treatment of colorectal liver metastases[J].Acta Oncol,2013,52(5):971-977.
[2] 刘波,罗强,王洪林.射频消融在肝癌治疗中的应用进展[J].河北药,2017,39(6):926-929.
[3] Li Y,Zheng YB,Zhao W,et al. Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma[J].Med Oncol,2013,30(4):1-6.
[4] 刘红梅,史丽丽,李金瑞,等.射频消融术联合DC-CIK治疗中晚期肝细胞癌的疗效及其对患者生命质量的影响[J].海南医学,2015,26(21):3136-3140.
[5] Jang HJ,Kim BC,Kim HS,et al.Comparison of RECIST 1.0 and RECIST 1.1 on computed tomography in patients with metastatic colorectal cancer[J].Int J Cancer,2014,86(2):117-121.
[6] 俞南松,严培军,郑媛媛,等.射频消融联合索拉非尼治疗中晚期肝癌对患者肝功能的影响及疗效分析[J].中华全科医学,2018,16(5):754-756.
[7] Jacobs A. Radiofrequency ablation for liver cancer[J].Radiol Technol,2015,86(6):645-664.
[8] 贾咏存,海金富,朴文花.DC-CIK 细胞免疫疗法对原发性肝癌患者免疫功能的影响[J].宁夏医科大学学报,2016,38( 2) : 144-147.
[9] 张厚云,陈书凯,李学敏,等.射频消融、高频热疗联合DC/ CIK细胞治疗中晚期肝癌的临床研究[J].临床和实验医学杂志,2018,17(3):287-290.
[10] 胡洪生,孙少华,沈丰,等.射频消融术联合DC-CIK治疗中晚期肝细胞癌患者疗效及其对生命质量的影响研究[J].实用肝脏病杂志,2018,21(5):757-760. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2021, 38(3): 455-457. |
|
|
|
|
2021, Vol. 38 
